Off-label prescribing might get boost from FDA
The Food and Drug Administration (FDA) is planning to replace the provision in the FDA Modernization Act (FDAMA) which is regarding the off-label use of drugs. This new rule will allow drug companies to distribute their journal articles discussing the off-label uses to physicians under some conditions.
A former federal health care prosecutor and litigation partner with Pillsbury named Dan Margolis said that this change will make it easier for pharmaceutical companies to disseminate truthful, non-misleading information than it was in the past, which is a big advantage for patients. It is to give attention to doctors to prescribe drugs for off-label uses all the time so that the public will get the information they need.
The plan imposes restrictions to make sure that the information is not misleading and truthful but may not give drug companies carte blanche to use journal reprint as part of an off-leading promotional campaign. Need help anything about healthcare? Dan P Neumeister can surely give solutions to your problems. Dan Neumeister used to be the Chief Operating Officer and the Senior Vice President of Enloe Health System. He also used to be the Senior Executive of the Medical Center, joined the Health System in 1997.
